Prostate cancer immunotherapy

Kenneth F. May, James L. Gulley, Charles G. Drake, Glenn Dranoff, Philip W. Kantoff

Research output: Contribution to journalArticle

Abstract

The interaction between the immune system and prostate cancer has been an area of research interest for several decades. The recent U.S. Food and Drug Administration approval of 2 first-in-class proof-of-concept immunotherapies (sipuleucel-T and ipilimumab) has stimulated broader interest in manipulating immunity to fight cancer. In the context of prostate cancer, the immunotherapy strategies that have garnered the most interest are the therapeutic vaccination strategies, exemplified by sipuleucel-T and PROSTVAC-VF, and immune checkpoint blockade of CTLA-4 and PD-1. Improved understanding of the immune responses generated by these strategies and development of predictive biomarkers for patient selection will guide rational combinations of these treatments and provide building blocks for future immunotherapies.

Original languageEnglish (US)
Pages (from-to)5233-5238
Number of pages6
JournalClinical Cancer Research
Volume17
Issue number16
DOIs
StatePublished - Aug 15 2011

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Prostate cancer immunotherapy'. Together they form a unique fingerprint.

  • Cite this

    May, K. F., Gulley, J. L., Drake, C. G., Dranoff, G., & Kantoff, P. W. (2011). Prostate cancer immunotherapy. Clinical Cancer Research, 17(16), 5233-5238. https://doi.org/10.1158/1078-0432.CCR-10-3402